These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 17153351)

  • 1. Kahalalide F and ES285: potent anticancer agents from marine molluscs.
    Faircloth G; Cuevas C
    Prog Mol Subcell Biol; 2006; 43():363-79. PubMed ID: 17153351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical armamentarium of marine-derived anti-cancer compounds.
    Jimeno JM
    Anticancer Drugs; 2002 May; 13 Suppl 1():S15-9. PubMed ID: 12173490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kahalalides V-Y isolated from a Hawaiian collection of the sacoglossan mollusk Elysia rufescens.
    Rao KV; Na MK; Cook JC; Peng J; Matsumoto R; Hamann MT
    J Nat Prod; 2008 May; 71(5):772-8. PubMed ID: 18407693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Convergent approaches for the synthesis of the antitumoral peptide, Kahalalide F. Study of orthogonal protecting groups.
    Gracia C; Isidro-Llobet A; Cruz LJ; Acosta GA; Alvarez M; Cuevas C; Giralt E; Albericio F
    J Org Chem; 2006 Sep; 71(19):7196-204. PubMed ID: 16958512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Total synthesis of bioactive peptides and depsipeptides from marine opisthobranch molluscs.
    Della Monica C; Della Sala G; De Riccardis F; Izzo I; Spinella A
    Prog Mol Subcell Biol; 2006; 43():333-61. PubMed ID: 17153350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of marine-derived anti-cancer compounds].
    Taguchi T
    Gan To Kagaku Ryoho; 2003 May; 30(5):579-88. PubMed ID: 12795086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mebamamide C, a deoxy analogue of mebamamides in Bryopsis marine green algae and Elysia sacoglossan mollusks.
    Komori S; Yamabe S; Matsuta R; Yamazaki Y; Fukuoka M; Sato S; Takada K
    Biosci Biotechnol Biochem; 2024 Mar; 88(4):399-404. PubMed ID: 38271606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances and limitations in the application of kahalalides for the control of cancer.
    Wyer S; Townsend DM; Ye Z; Kourtidis A; Choo YM; de Barros ALB; Donia MS; Hamann MT
    Biomed Pharmacother; 2022 Apr; 148():112676. PubMed ID: 35149387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron complexation to oxygen rich marine natural products: a computational study.
    Manning TJ; Williams J; Jarrard J; Gorman T
    Mar Drugs; 2010 Jan; 8(1):1-23. PubMed ID: 20161968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical defenses of the sacoglossan mollusk Elysia rufescens and its host Alga bryopsis sp.
    Becerro MA; Goetz G; Paul VJ; Scheuer PJ
    J Chem Ecol; 2001 Nov; 27(11):2287-99. PubMed ID: 11817082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tandem mass spectrometry of kahalalides: identification of two new cyclic depsipeptides, kahalalide R and S from Elysia grandifolia.
    Tilvi S; Naik CG
    J Mass Spectrom; 2007 Jan; 42(1):70-80. PubMed ID: 17149796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kahalalide derivatives from the Indian sacoglossan mollusk Elysia grandifolia.
    Ashour M; Edrada R; Ebel R; Wray V; Wätjen W; Padmakumar K; Müller WE; Lin WH; Proksch P
    J Nat Prod; 2006 Nov; 69(11):1547-53. PubMed ID: 17125219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid identification of a protein binding partner for the marine natural product kahalalide F by using reverse chemical proteomics.
    Piggott AM; Karuso P
    Chembiochem; 2008 Mar; 9(4):524-30. PubMed ID: 18224648
    [No Abstract]   [Full Text] [Related]  

  • 14. Development of a lyophilized parenteral pharmaceutical formulation of the investigational polypeptide marine anticancer agent kahalalide F.
    Nuijen B; Bouma M; Talsma H; Manada C; Jimeno JM; Lopez-Lazaro L; Bult A; Beijnen JH
    Drug Dev Ind Pharm; 2001 Sep; 27(8):767-80. PubMed ID: 11699828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Technology evaluation: Kahalalide F, PharmaMar.
    Hamann MT
    Curr Opin Mol Ther; 2004 Dec; 6(6):657-65. PubMed ID: 15663330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and structure determination of kahalalide F (1,2).
    López-Macià A; Jiménez JC; Royo M; Giralt E; Albericio F
    J Am Chem Soc; 2001 Nov; 123(46):11398-401. PubMed ID: 11707116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compatibility and stability of the investigational polypeptide marine anticancer agent kahalalide F in infusion devices.
    Nuijen B; Bouma M; Manada C; Jimeno JM; Lazaro LL; Bult A; Beijnen JH
    Invest New Drugs; 2001; 19(4):273-81. PubMed ID: 11561686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marine natural products.
    Blunt JW; Copp BR; Keyzers RA; Munro MHG; Prinsep MR
    Nat Prod Rep; 2017 Mar; 34(3):235-294. PubMed ID: 28290569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New drugs from the sea.
    D'Incalci M; Simone M; Tavecchio M; Damia G; Garbi A; Erba E
    J Chemother; 2004 Nov; 16 Suppl 4():86-9. PubMed ID: 15688619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Marine Peptides as Anticancer Agents: A Remedy to Mankind by Nature.
    Negi B; Kumar D; Rawat DS
    Curr Protein Pept Sci; 2017; 18(9):885-904. PubMed ID: 27455970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.